Pulmonary hypertension (PH) is an infrequently reported complication of multiple myeloma (MM). PH has been more commonly associated with amyloidosis, myeloproliferative diseases, and the POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome. PH in MM is typically mild to moderate and may be secondary to a variety of conditions, which include left ventricular dysfunction, high-output cardiac failure, chronic kidney disease, treatment-related toxicities, and precapillary involvement. We describe 3 patients with MM and severe PH. Each patient underwent right heart catheterization. All patients demonstrated elevated pulmonary pressures, transpulmonary gradients, and pulmonary vascular resistance. Each patient was ultimately treated with pulmonary vasodilator therapy with improvement in cardiopulmonary symptoms. Additional studies are needed to define the prevalence, prognosis, and pathogenesis of PH in this complex population and to help clarify who may benefit from targeted PH therapy.Keywords: pulmonary hypertension, multiple myeloma, pulmonary vasculature, amyloidosis. Multiple myeloma (MM) is a hematological malignancy characterized by the neoplastic proliferation of plasma cells within bone marrow and extramedullary sites. It is distinguished from other disorders of plasma cell proliferation by the presence of CRAB features, defined as hypercalcemia, renal insufficiency, anemia, and lytic bone lesions. 1 Although cardiovascular pathology has been frequently associated with MM, pulmonary hypertension (PH), which is characterized by elevated pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR), is not a commonly recognized complication. We report the clinical and hemodynamic features of 3 patients with established MM and severe PH. We also provide a review of the literature and discuss the different pathways for development of PH in this mixed population.
CASE DESCRIPTION Case 1Patient 1 was a 72-year-old man who presented to the PH clinic with exertional dyspnea. His medical history was significant for immunoglobulin A (IgA) κ MM treated with hematopoietic autologous stem cell transplantation (HSCT) 3 years earlier. At the time of presentation, the patient was receiving maintenance chemotherapy with lenalidomide to help extend clinical remission. In addition, he had a history of permanent atrial fibrillation and severe aortic stenosis. Physical examination revealed a 3/6 crescendo-decrescendo murmur at the upper sternal base radiating to the carotids and a soft 1/6 holosystolic murmur at the lower sternal base. Transthoracic echocardiography (TTE) revealed an ejection fraction (EF) of 62%, a dilated left atrium (LA), pulmonary artery systolic pressure (PASP) of 83 mmHg, flattening of the interventricular septum, a severely dilated right ventricle (RV) and right atrium (RA), mildly reduced RV function, and an aortic valve area of 0.73 cm 2 . A right heart catheterization (RHC) showed PAP of 96/32 mmHg (mean, 53 mmHg) with a left ventricular (L...